Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$161.97 USD

161.97
575,208

+1.87 (1.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 6% (16 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Best Growth Stocks to Buy for January 18th

by Zacks Equity Research

DVA, CAH and ZM made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 18, 2024.

Best Value Stocks to Buy for January 18th

by Zacks Equity Research

DVA, CAH and BBVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on January 18, 2024.

New Strong Buy Stocks for January 18th

by Zacks Equity Research

PD, EGO, HMC, DVA and BBVA have been added to the Zacks Rank #1 (Strong Buy) List on January 18, 2024.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) on strong uptake of the myAir app with AirSense11.

Abbott's (ABT) Innovations Aid, Macroeconomic Issues Stay

by Zacks Equity Research

Abbott (ABT) is successfully continuing the rollout of Alinity, the company's fully integrated and automated molecular diagnostics analyzer.

ClearPoint Neuro (CLPT) Gets FDA's Nod for SmartFrame OR System

by Zacks Equity Research

ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to serve a wider patient pool than its legacy portfolio.

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

by Zacks Equity Research

Investors continue to be optimistic about Thermo Fisher (TMO) due to its series of new product launches and promising growth strategy.

Here's Why You Should Add McKesson (MCK) to Your Portfolio Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

Here's Why Investors Should Retain Bruker (BRKR) Stock Now

by Zacks Equity Research

Investors are optimistic about Bruker (BRKR) on solid prospects of BSI Nano group and raised guidance.

Illumina (ILMN) Shares Down 1.2% Post Preliminary Q4 Results

by Zacks Equity Research

Illumina's (ILMN) fourth-quarter 2023 results are likely to reflect the impacts of the adoption of its new generation of distributed liquid biopsy assay.

Should Value Investors Buy DaVita (DVA) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here's Why You Should Retain Masimo (MASI) Stock for Now

by Zacks Equity Research

Masimo's (MASI) R&D activities raise optimism about the stock.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

IDEXX (IDXX) Enhances Fecal Dx Antigen Testing Platform

by Zacks Equity Research

IDEXX's (IDXX) Fecal Dx antigen testing detects the most prevalent and clinically relevant intestinal parasites in dogs and cats.

Integer Holdings (ITGR) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.

Veeva Systems (VEEV) Offerings Adopted by SK Life Science

by Zacks Equity Research

Veeva Systems' (VEEV) Vault Validation Management is expected to aid SK Life Science to accelerate validation processes for increased inspection readiness.

Best Growth Stocks to Buy for January 15th

by Zacks Equity Research

DVA, AZZ and ELF made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 15, 2024.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: DaVita, Block, Home Depot in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Quest Diagnostics (DGX) Inks New Deal With Ultima Genomics

by Zacks Equity Research

Quest Diagnostics' (DGX) new partnership is likely to leverage its oncology expertise and national scale.

Here's Why You Should Buy Align Technology (ALGN) Stock Now

by Zacks Equity Research

Investors remain optimistic about Align Technology (ALGN) due to the progress in the Invisalign portfolio and highly favorable solvency.

Shaun Pruitt headshot

Don't Overlook These Top Value Stocks in January It's Time to Buy

by Shaun Pruitt

With "A" Zacks Style Scores grades for Value here are three top-rated stocks with fundamental valuations that shouldn't be overlooked at the moment.

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) owing to growth in the RMS and DSA segments and stable solvency position.

Inari (NARI) Preliminary Q4 Revenues Ride on Procedure Demand

by Zacks Equity Research

Inari's (NARI) preliminary revenues reflect healthy procedure volume growth on the back of the rising adoption of existing and newly launched products in the United States and international markets.